Fig. 2: WM-3835 provokes apoptosis in primary CRPC cells.
The primary human prostate cancer cells derived from a CRPC patient, “pPC-1”, were treated with WM-3835 (10 μM) or vehicle control (“Veh”) for designated hours, caspase-PARP activation was measured (A–C); Cell apoptosis was tested by nuclear TUNEL staining assay (D). pPC-1 cells were pretreated with zDEVD-fmk (45 μM), zVAD-fmk (45 μM), or DMSO (0.1%) for 1 h, followed by WM-3835 (10 μM) treatment for another 72 h, cell death was tested by LDH releasing assay (E). The primary human prostate cancer cells derived from three other CRPC patients, “pPC-2/pPC-3/pPC-4” (F, G), or the primary human prostate epithelial cells (“pEpi1” and “pEpi2”, derived from two patients) (H) were treated WM-3835 (10 μM) or vehicle control (“Veh”) for designated hours, caspase-3 activity (F), and apoptosis (G, H) were tested using the similar methods. Data were expressed as the mean ± standard deviation (SD, n = 5). *P < 0.05 versus “Veh” group. #P < 0.05 versus “DMSO” treatment (E). “n. s.” stands for non-statistical difference (P > 0.05). Scale bar = 100 μm.
